{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:55:28Z","timestamp":1791269728120,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.schres.2025.12.015","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T23:13:01Z","timestamp":1767827581000},"page":"86-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5)"],"prefix":"10.1016","volume":"288","author":[{"given":"Inder","family":"Kaul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Chaturvedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejendra","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsiuanlin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Sawchak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Sauder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2025.12.015_bb0005","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.schres.2025.12.015_bb0010","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"issue":"12","key":"10.1016\/j.schres.2025.12.015_bb0015","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/j.euroneuro.2013.09.001","article-title":"Drug attitude and other predictors of medication adherence in schizophrenia: 12 months of electronic monitoring (MEMS(\u00ae)) in the Swedish COAST-study","volume":"23","author":"Brain","year":"2013","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.schres.2025.12.015_bb0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.schres.2025.12.015_bb0025","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1017\/S1092852915000917","article-title":"Long-term safety and effectiveness of lurasidone in schizophrenia: a 22-month, open-label extension study","volume":"21","author":"Correll","year":"2016","journal-title":"CNS Spectr."},{"issue":"1","key":"10.1016\/j.schres.2025.12.015_bb0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1017\/S1092852917000220","article-title":"Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study","volume":"23","author":"Cutler","year":"2018","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2025.12.015_bb0035","first-page":"20","article-title":"A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia","volume":"12","author":"Dibonaventura","year":"2012","journal-title":"B.M.C. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2025.12.015_bb0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/YIC.0b013e328314e1f3","article-title":"Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies","volume":"23","author":"Emsley","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"5","key":"10.1016\/j.schres.2025.12.015_bb0045","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ijnp\/pyy002","article-title":"A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as maintenance treatment in adults with schizophrenia","volume":"21","author":"Forbes","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.schres.2025.12.015_bb0050","series-title":"ECDEU Assessment Manual for Psychopharmacology. Revised","author":"Guy","year":"1976"},{"issue":"3","key":"10.1016\/j.schres.2025.12.015_bb0055","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1176\/appi.ajp.20240076","article-title":"The impact of xanomeline and trospium chloride on cognitive impairment in acute schizophrenia: replication in pooled data from two phase 3 trials","volume":"182","author":"Horan","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"10202","key":"10.1016\/j.schres.2025.12.015_bb0060","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","author":"Huhn","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.schres.2025.12.015_bb0065","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.4088\/JCP.18com12123","article-title":"Clinical guidance on the identification and management of treatment-resistant schizophrenia","volume":"80","author":"Kane","year":"2019","journal-title":"J. Clin. Psychiatry"},{"issue":"10422","key":"10.1016\/j.schres.2025.12.015_bb0070","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0140-6736(23)02190-6","article-title":"Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial","volume":"403","author":"Kaul","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.schres.2025.12.015_bb0075","first-page":"749","article-title":"Efficacy and safety of xanomeline-trospium chloride in schizophrenia: a randomized clinical trial","volume":"81","author":"Kaul","year":"2024","journal-title":"J.A.M.A. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.015_bb0080","article-title":"Long-term safety and efficacy of xanomeline and trospium chloride in schizophrenia: a 52-week, open-label extension trial (EMERGENT-4)","author":"Kaul","year":"2025","journal-title":"Am. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2025.12.015_bb0085","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.24m15497","article-title":"Safety and tolerability of KarXT (xanomeline and trospium) in schizophrenia: pooled results from the 5-week, randomized, double-blind, placebo-controlled EMERGENT Trials","volume":"86","author":"Kaul","year":"2025","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.015_bb0090","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1192\/S0007125000291514","article-title":"The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation","volume":"7","author":"Kay","year":"1989","journal-title":"Br. J. Psychiatry Suppl."},{"issue":"10","key":"10.1016\/j.schres.2025.12.015_bb0095","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"J. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2025.12.015_bb0100","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/0149-2918(95)80105-7","article-title":"Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia","volume":"17","author":"Lindstr\u04e7m","year":"1995","journal-title":"Clin. Ther."},{"issue":"18","key":"10.1016\/j.schres.2025.12.015_bb0105","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1056\/NEJMra1808803","article-title":"Schizophrenia","volume":"381","author":"Marder","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.schres.2025.12.015_bb0110","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1097\/YIC.0000000000000038","article-title":"Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study","volume":"29","author":"McDonnell","year":"2014","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2025.12.015_bb0115","doi-asserted-by":"crossref","DOI":"10.1017\/S1092852924002244","article-title":"How antipsychotics work in schizophrenia: a primer on mechanisms","volume":"30","author":"Meyer","year":"2024","journal-title":"CNS Spectr."},{"key":"10.1016\/j.schres.2025.12.015_bb0120","article-title":"The mechanism of action of clozapine","volume":"2698811251319458","author":"Morrison","year":"2025","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.schres.2025.12.015_bb0125","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.21101083","article-title":"Muscarinic acetylcholine receptor agonists as novel treatments for schizophrenia","volume":"179","author":"Paul","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.015_bb0130","series-title":"SAS\/ACCESSR 9.4 Interface to ADABAS: Reference","author":"SAS Institute","year":"2013"},{"issue":"Suppl. 20","key":"10.1016\/j.schres.2025.12.015_bb0135","first-page":"22","article-title":"The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.015_bb0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.schres.2025.12.015_bb0145","series-title":"Stahl's Essential Pharmacology","author":"Stahl","year":"2021"},{"key":"10.1016\/j.schres.2025.12.015_bb0150","author":"U.S. Food and Drug Administration"},{"key":"10.1016\/j.schres.2025.12.015_bb0155","series-title":"Presented at: American College of Neuropsychopharmacology; December 8-11","article-title":"Effects of KarXT (xanomeline and trospium chloride) on ambulatory blood pressure: results from an open-label, multicenter trial in participants with schizophrenia","author":"Vandell","year":"2024"},{"issue":"Suppl. 4","key":"10.1016\/j.schres.2025.12.015_bb0160","first-page":"1","article-title":"The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness","volume":"70","author":"Velligan","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2025.12.015_bb0165","article-title":"The potential of muscarinic M(1) and M(4) receptor activators for the treatment of cognitive impairment associated with schizophrenia","volume":"15","author":"Yohn","year":"2024","journal-title":"Front. Psych."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425004335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996425004335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T23:44:45Z","timestamp":1770335085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996425004335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":33,"alternative-id":["S0920996425004335"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2025.12.015","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term efficacy, safety, and tolerability of xanomeline and trospium chloride in schizophrenia: A 52-week, open-label trial (EMERGENT-5)","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2025.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}